Publikationen suchen
- Publikation
- Autoren
- Einrichtungen
- Abstract
- Externe Dokumente
- Links
De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab +/- weekly paclitaxel
(
Zeitschriftenartikel
)
